Efficacy and safety in mice of repeated, lifelong administration of an ANGPTL3 vaccine

Hirotaka Fukami; Jun Morinaga; Hironori Nakagami; Hiroki Hayashi; Yusuke Okadome; Eiji Matsunaga; Tsuyoshi Kadomatsu; Haruki Horiguchi; Michio Sato; Taichi Sugizaki; Keishi Miyata; Daisuke Torigoe; Masashi Mukoyama; Ryuichi Morishita; Yuichi Oike

doi:10.1038/s41541-023-00770-3

Efficacy and safety in mice of repeated, lifelong administration of an ANGPTL3 vaccine

NPJ Vaccines. 2023 Nov 1;8(1):168. doi: 10.1038/s41541-023-00770-3.

Authors

Hirotaka Fukami^{1

2

3}, Jun Morinaga^{4

5

6}, Hironori Nakagami⁷, Hiroki Hayashi⁷, Yusuke Okadome¹, Eiji Matsunaga^{1

2

3}, Tsuyoshi Kadomatsu^{1

3}, Haruki Horiguchi^{1

3

8}, Michio Sato^{1

3}, Taichi Sugizaki^{1

3}, Keishi Miyata^{1

3}, Daisuke Torigoe^{1

9}, Masashi Mukoyama², Ryuichi Morishita¹⁰, Yuichi Oike^{11

12

13

14}

Affiliations

¹ Department of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto-shi, 860-8556, Japan.
² Department of Nephrology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto-shi, 860-8556, Japan.
³ Center for Metabolic Regulation of Healthy Aging (CMHA), Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto-shi, 860-8556, Japan.
⁴ Department of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto-shi, 860-8556, Japan. morijun@kumamoto-u.ac.jp.
⁵ Department of Nephrology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto-shi, 860-8556, Japan. morijun@kumamoto-u.ac.jp.
⁶ Center for Metabolic Regulation of Healthy Aging (CMHA), Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto-shi, 860-8556, Japan. morijun@kumamoto-u.ac.jp.
⁷ Department of Health Development and Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita-shi, 565-0871, Japan.
⁸ Department of Aging and Geriatric Medicine, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto-shi, 860-8556, Japan.
⁹ Institute of Resource Development and Analysis (IRDA), Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto-shi, 860-0811, Japan.
¹⁰ Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita-shi, 565-0871, Japan.
¹¹ Department of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto-shi, 860-8556, Japan. oike@gpo.kumamoto-u.ac.jp.
¹² Center for Metabolic Regulation of Healthy Aging (CMHA), Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto-shi, 860-8556, Japan. oike@gpo.kumamoto-u.ac.jp.
¹³ Department of Aging and Geriatric Medicine, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto-shi, 860-8556, Japan. oike@gpo.kumamoto-u.ac.jp.
¹⁴ Institute of Resource Development and Analysis (IRDA), Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto-shi, 860-0811, Japan. oike@gpo.kumamoto-u.ac.jp.

Abstract

Previously, we reported that an ANGPTL3 vaccine is a hopeful therapeutic option against dyslipidemia. In our current study, we assess durability and booster effects of that vaccine over a period representing a mouse's lifespan. The vaccine remained effective for over one year, and booster vaccination maintained suppression of circulating triglyceride levels thereafter without major adverse effects on lungs, kidneys, or liver, suggesting vaccine efficacy and safety.

Abstract

Grants and funding